Research Article
Effect of Therapeutic Inhibition of TNF on Circulating Endothelial Progenitor Cells in Patients with Rheumatoid Arthritis
| F/M | 14/3 | Age—yrs | | Mean ± SD (range) | (26–68) | Disease duration—months | | Mean ± SD (range) | (24–360) | DAS28 baseline | | Mean ± SD (range) | (4.27–7.78) | DAS28 followup | | Mean ± SD (range) | (0.56–4.03)* | Glucocorticoid dose (mg) baseline | | Mean ± SD (range) | (5–20)** | Glucocorticoid dose (mg) followup | | Mean ± SD (range) | (5–7.5)** | Methotrexate | 10/17 | Leflunomide | 3/17 | Sulfasalazine | 3/17 | Adalimumab | 3/17 | Etanercept | 14/17 |
|
|
DAS28: disease activity score 28. versus baseline value, **prednisone-equivalent.
|